USE OF EXOGENIC PHOSPHOCREATINE IN PREVEN TION AND TREATMENT OF HEART-FAILURE IN MYOCARDIAL-INFARCTION PATIENTS

Central, intracardiac hemodynamics and myocardial contractility were a ssessed in 97 inpatients with macrofocal myocardial infarction. Of the m, 71 received conventional chemotherapy versus 26 patients given addi tionally intravenous phosphocreatine (neoton). The total dose of neoto n 30 g was injected during the course of 6 days following the disease onset. With minimal changes in central hemodynamics, phosphocreatine w as found to prevent left-ventricular dilatation and development of con gestive heart failure by decreasing preload, to maintain myocardial co ntractility without reduction.